Pfizer reports its experimental pill to treat COVID-19 appears effective against the omicron variant.
The company also said full results of its 2,250-person study confirmed the pill’s promising early results against the COVID-19 virus.
Separate laboratory testing shows the drug retains its potency against the omicron variant, the company said, as many experts had predicted. Pfizer tested the antiviral drug against a man-made version of a key protein that omicron uses to reproduce itself.